FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This new facility strengthens Latin America as a collaborative hub
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
These findings follow positive Phase 3 results presented earlier this year
Subscribe To Our Newsletter & Stay Updated